Neurology

Clearmind Medicine's CMND-100 Meets Primary Endpoint in Phase I/IIa Trial for Alcohol Use Disorder

FDA · Alcohol Use Disorder (AUD) · 3 min

FDA Approves Ztalmy: First Therapy for CDKL5 Deficiency Seizures

FDA · neurology · 4 min

FDA Grants Accelerated Approval to Eli Lilly's Donanemab for Alzheimer's

FDA · Neurology · 5 min